New additions to leadership signal commercial readiness and an expanding clinical roadmap MASON, Ohio–(BUSINESS WIRE)–Genetesis, Inc., the leader in biomagnetic cardiac imaging solutions, today announced the appointment of three new members to the executive leadership team who will oversee and execute key aspects of commercialization and clinical research for its […]
Other News
Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil™ Drug-Coated Balloon
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced it has received a letter from the U.S. Food and Drug Administration (FDA; the Agency) related to its premarket approval (PMA) application for the SurVeil™ drug-coated […]
Intermountain Healthcare and Story Health Partner to Transform Specialty Care for Patients with Heart Failure
Partnership to Improve Access to High-Quality Continuous Specialty Care with Story Health’s Innovative Platform CUPERTINO, Calif., Jan. 19, 2023 /PRNewswire/ — Intermountain Healthcare, a leading health system of 33 hospitals in seven states, and Story Health, a health technology and services company that provides scalable specialty care beyond the clinic, have entered into a […]
Differentiated Capabilities of Surmodics’ Crystalline Drug Release Platform for Sirolimus-Coated Balloons Presented at ISET Conference
Surmodics’ proprietary Crystalline Drug Release (CDR) platform enhances sirolimus stability, transfer, and retention in tissue CDR discussed in connection with 12-month data from Surmodics’ SWING trial of the Sundance™ Sirolimus-Coated Balloon January 19, 2023 08:30 AM Eastern Standard Time EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ:SRDX) (the “Company”), a leading provider of […]
Renibus Therapeutics Announces Oral Presentation on RBT-1 Phase 2 Results at 2023 Society of Critical Care Medicine (SCCM) Meeting
-RBT-1 met the primary biomarker endpoint as well as several key clinical endpoints; positive data supports the potential for RBT-1 to improve postoperative outcomes in cardiothoracic surgery- –RBT-1 treatment demonstrated a statistically significant reduction in ICU days and 30-day cardiopulmonary readmission rates; patients treated with RBT-1 had reduced time on […]
Varian Receives Investigational Device Exemption for Cardiac Radioablation Clinical Trial, RADIATE-VT
Trial Represents an Opportunity to Evaluate a Non-Invasive Treatment Option for Patients with High-Risk Refractory Ventricular Tachycardia PALO ALTO, Calif., Jan. 19, 2023 /PRNewswire/ — Varian, a Siemens Healthineers company, announced today that the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) for the pivotal RADIATE-VTTM clinical trial. The RADIATE-VT trial […]
BioSig Issues Shareholder Update to Highlight Recent Achievements and Ongoing Developments
To date, the Company’s FDA 510(k)-cleared PURE EP™ System has been used in approximately 3,000 patient cases across the United States The Company has built a robust pipeline of commercial sale prospects and expects multiple closings in first half of 2023 New supporting clinical data to be published BioSig Technologies, […]
Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal
— Full results published in European Heart Journal Open — — Study met primary safety endpoint — — All patients alive, transplant-free, and maintained expected rate of growth one year after treatment — — Data supports ongoing clinical development of Lomecel-BTM for HLHS, currently being evaluated in a Phase 2a trial — […]
Daxor Corporation Joins the Heart Failure Society of America (HFSA) as a Corporate Member
Oak Ridge, TN, Jan. 19, 2023 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces joining the Heart Failure Society of America (HFSA) as a corporate member to collaborate and deepen engagement with leaders in the field of heart failure. “The HFSA is the premier […]
Cardurion Pharmaceuticals Strengthens Leadership Team with Appointment of Elizabeth Radcliffe as Chief Financial Officer
Strategic Finance Leader Brings Deep Biopharmaceutical Industry Experience and Track Record of Successful Leadership BURLINGTON, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of Elizabeth Radcliffe […]



